Clover Health Investments is trading lower Tuesday afternoon after the Trump administration proposed flat MA payment rates for 2027.

Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. See why I rate the CLOV stock a Buy.

Over the last six months, Clover Health’s shares have sunk to $2.60, producing a disappointing 13.5% loss - a stark contrast ...

Medicare Advantage (MA) insurer Clover Health is leaning on strong performance in the annual enrollment period and financial ...

What Happened? Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 2.5% in the afternoon session after ...

Clover Health Investments (CLOV) drew fresh attention after reporting a 53% year-over-year jump in Medicare Advantage PPO ...

Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 10% in the afternoon session after the company ...

Clover Health Investments Corp (NASDAQ: CLOV) stock is rising Wednesday after the company announced that it expects to ...

Clover Health Investments, Corp. reported a 27% increase in year-over-year Medicare Advantage membership during the recent Annual Election Period, reaching over 100,000 members, with 95% enrolled in ...

Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117.4 million year-over-year and year-to-date Adjusted EBITDA by $87.2 million year-over-year Increases Full-Year 2024 ...

Clover Health Investments, Corp. announced that its Chief Financial Officer, Peter Kuipers, will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 11:00 a.m. ET, ...